Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and-3(v1) trials
Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and-3(v1) trials
复制标题
DOI：
10.1038/sj.bjc.6604838
复制
发表时间：
2009-01-22
影响因子：
8.8
通讯作者：
Buechler, M. W.
中科院分区：
文献类型：
--
作者：
Neoptolemos, J. P.;Stocken, D. D.;Buechler, M. W.
ESPAC-1、ESPAC-1 plus和早期ESPAC-3（v1）结果（458例随机化患者; 364例死亡）用于使用荟萃分析评估辅助5 FU/FA与单纯切除术治疗胰腺癌的有效性。合并风险比为0. 70（95% CI = 0. 55 - 0. 88）P = 0. 003，5 FU/FA组的中位生存期为23. 2（95% CI = 20. 1 - 26. 5）个月，而单纯切除术组为16. 8（95% CI = 14. 3 - 19. 2）个月，支持在胰腺癌中使用辅助5 FU/FA。
The ESPAC-1, ESPAC-1 plus, and early ESPAC-3(v1) results (458 randomized patients; 364 deaths) were used to estimate the effectiveness of adjuvant 5FU/FA vs resection alone for pancreatic cancer using meta-analysis. The pooled hazard ratio of 0.70 (95% CI = 0.55-0.88) P = 0.003, and the median survival of 23.2 (95% CI = 20.1-26.5) months with 5FU/FA vs 16.8 (95% CI = 14.3-19.2) months with resection alone supports the use of adjuvant 5FU/FA in pancreatic cancer.